Enhanced Alpha-1 Antitrypsin Administration for Reduced Risk of Acute Graft Versus Host Disease

This inventive concept presents a suite of direct improvements and enhancements to the original patent, focusing on optimizing alpha-1 antitrypsin administration schedules, synergistic immunosuppressive agents, and real-time monitoring systems to reduce the risk of acute graft versus host disease after hematopoietic cell transplantation.

The original patent disclosed methods for reducing the risk of graft versus host disease in patients receiving hematopoietic cell transplantation by administering alpha-1 antitrypsin. However, the patent's limitations include the lack of personalized treatment approaches, limited understanding of synergistic immunosuppressive agents, and the need for more efficient monitoring systems. This inventive concept addresses these limitations by introducing a computer-implemented algorithm for optimizing alpha-1 antitrypsin administration schedules, synergistic immunosuppressive agents, and real-time monitoring systems.

The inventive concept comprises four main components: (1) a system for optimizing alpha-1 antitrypsin administration schedules based on patient-specific risk factors and transplant type, (2) a method for treating acute graft versus host disease by administering alpha-1 antitrypsin in combination with synergistic immunosuppressive agents, (3) a kit for reducing the risk of onset of acute graft versus host disease, and (4) a system for monitoring and adjusting alpha-1 antitrypsin administration in real-time during hematopoietic cell transplantation. The computer-implemented algorithm uses machine learning to analyze patient data and recommend personalized treatment schedules. The synergistic immunosuppressive agents are selected based on their ability to enhance the therapeutic effect of alpha-1 antitrypsin. The kit includes a pre-filled syringe containing alpha-1 antitrypsin, a patient information leaflet, and a schedule optimization software for healthcare professionals. The real-time monitoring system uses wearable devices, cloud-based data analytics, and clinician notification systems to track patient vital signs and alert healthcare professionals of potential acute graft versus host disease onset.

The inventive concept's novelty lies in the integration of machine learning algorithms, synergistic immunosuppressive agents, and real-time monitoring systems to optimize alpha-1 antitrypsin administration schedules and reduce the risk of acute graft versus host disease. The inventive step is the combination of these components to provide a personalized, efficient, and effective treatment approach that overcomes the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, additional synergistic immunosuppressive agents, or alternative monitoring systems. Variations of the kit could include different formulations of alpha-1 antitrypsin or additional patient information materials.

The inventive concept has significant commercial potential in the hematopoietic cell transplantation market, with potential applications in hospitals, clinics, and research institutions. The market for acute graft versus host disease treatment is growing, and this inventive concept offers a competitive advantage by providing a personalized, efficient, and effective treatment approach.